Histogenics Corp (NASDAQ:HSGX) saw strong trading volume on Wednesday . 54,039,674 shares were traded during trading, an increase of 437% from the previous session’s volume of 10,059,263 shares.The stock last traded at $0.30 and had previously closed at $0.22.

The firm has a market cap of $28.39 million, a P/E ratio of -0.37 and a beta of 3.46.

A number of hedge funds have recently made changes to their positions in HSGX. Geode Capital Management LLC purchased a new stake in Histogenics during the fourth quarter valued at approximately $25,000. Virtu Financial LLC increased its holdings in Histogenics by 505.8% during the first quarter. Virtu Financial LLC now owns 592,976 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 495,096 shares during the last quarter. Finally, Sabby Management LLC purchased a new stake in Histogenics during the first quarter valued at approximately $220,000. 11.37% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/histogenics-nasdaqhsgx-sees-strong-trading-volume/3041700.html.

Histogenics Company Profile (NASDAQ:HSGX)

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

See Also: Growth Stocks, What They Are, What They Are Not

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.